About a month after securing a label expansion from the FDA for multidose pen versions of Zepbound, Eli Lilly is making the KwikPens available to self-paying users of its direct-to-consumer drug sales platform.
Each single-patient-use KwikPen holds four doses of Zepbound, comprising a one-month supply of the obesity and obstructive sleep apnea med. The pens will start at $299 per month for the initial 2.5-mg dose, Lilly said in a release Monday.
The company didn’t specify pricing for other dosages of the drug, but it said in an early November announcement about its agreement with the Trump administration that, once approved in the U.S., the multidose Zepbound KwikPens would be available to self-pay patients in the States for “no more than $449.”
Lilly noted at the time that the planned prices were comparable to those available in Europe—nodding to the administration’s desire to reduce U.S. drug prices and bring them closer in line with other developed nations—and that they would represent a $50 discount from previous direct-to-patient prices.
The FDA approval (PDF) for the new Zepbound format arrived in late January, alongside a corresponding nod (PDF) for Mounjaro KwikPens in diabetes, and follows other regulatory OKs for the multidose devices around the world. Lilly also sells several of its insulin medications in KwikPen form.
In Monday’s announcement, Ilya Yuffa, president of Lilly USA and global customer capabilities, framed the Zepbound KwikPen rollout as part of the company’s “commitment to supporting people living with obesity in their weight management journey.”
Yuffa touted Zepbound as “the #1 prescribed injectable obesity‑management medication,” and the company cited IQVIA prescription data to add that “one out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials in 2025.”
Lilly said that for now, the multidose pens will be available with a valid prescription through its LillyDirect platform only “for new or existing self-pay patients.” On the LillyDirect website, self-paying customers can also opt for single-dose vials of Zepbound, while those using commercial insurance may select only prefilled single-dose pens.
The KwikPen prices match up with recent reductions to those for the single-dose vials of Zepbound sold through LillyDirect. At the start of December, Lilly slashed the self-pay prices for all dosages of the vials by a range of $50 to $150, with the starting 2.5-mg dose brought down to $299 and the highest doses maxing out at $449.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.